The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern (Q37898750)

25 August 2017

1 reference

title

The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern (English)

1 reference

25 August 2017

0 references

1 reference

C J Currie

1

1 reference

PubMed ID

21736688

25 August 2017

J A Johnson

series ordinal

2

1 reference

25 August 2017

21 November 2011

1 reference

Diabetes, Obesity and Metabolism

25 August 2017

1 reference

25 August 2017

14

1 reference

25 August 2017

1-4

1 reference

25 August 2017

1

1 reference

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

25 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Intensified glucose lowering in type 2 diabetes: time for a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Insulin resistance: from bit player to centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

The kidney: an unwilling accomplice in syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Mitogenic action of insulin: friend, foe or 'frenemy'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Insulin use and increased risk of mortality in type 2 diabetes: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Diabetes mellitus, fasting glucose, and risk of cause-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

The proliferating role of insulin and insulin-like growth factors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Excess exposure to insulin is the primary cause of insulin resistance and its associated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Insulin: potential negative consequences of early routine use in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01469.X

10.1111/J.1463-1326.2011.01469.X

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21736688